RecruitingPhase 2NCT07382739
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Sponsor
M.D. Anderson Cancer Center
Enrollment
34 participants
Start Date
Mar 31, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Eligibility
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Elranatamab for people with elranatamab, extramedullary disease in multiple myeloma, and other related conditions. The study is currently recruiting participants at 1 location.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGElranatamab
Given by IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07382739
Related Trials
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT0628531868 locations
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
NCT076099402 locations
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT074558515 locations
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
NCT072837311 location
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT070327143 locations